Improving the Childbirth Experience for Women Who Have Undergone Cervical Ripening by Involving Them in the Choice of Ripening Technique (AVAPAM)
Improving the Childbirth Experience for Women Who Have Undergone Cervical Ripening by Involving Them in the Choice of Ripening Technique : a Before-and-after Study
This is a prospective, single-centre, quasi-experimental before-and-after study. Women due to give birth at the participating centre will be informed about the study during their 9th-month antenatal appointment. Only expectant mothers for whom cervical ripening is indicated will be included. During the BEFORE period, cervical ripening will be offered to them according to the method chosen by the healthcare team following a discussion of their case at a team meeting. During the AFTER period, the various possible methods of cervical ripening will be offered to the patient, and the choice of method will be left to her.
The participants' experiences will be compared using the QEVA self-assessment questionnaire, completed two days after delivery.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Induction of labour is a common practice in France, and the rate is rising. Cervical ripening and induction of labour are often associated with negative maternal experiences of labour and childbirth. The experience of childbirth has a significant influence on the early mother-child relationship, as well as on the relationship between the parents. A negative experience of childbirth is a major risk factor for postnatal depression and post-traumatic stress disorder.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Mélanie JUNKE
- 電話番号:0033387179886
- メール:projet-recherche-clinique@chr-metz-thionville.fr
研究場所
-
-
-
Peltre、フランス、57245
- CHR METZ-THIONVILLE, Hôpital Femme Mère Enfant
-
コンタクト:
- Mélanie JUNKE
- 電話番号:0033387179886
- メール:projet-recherche-clinique@chr-metz-thionville.fr
-
主任研究者:
- Dr Cristina-Elena DOROFTE, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Female patients aged over 18
- Patients who gave their written consent after receiving information to enable them to make an informed decision about the study
- Patients with a medical or non-medical indication for induction of labour who are admitted to the maternity ward of the participating centre
Exclusion Criteria:
- Patients with a history of uterine scarring (a history of uterine scarring is a contraindication to prostaglandins)
- Patients requiring urgent maturation
- Patients requiring induction of labour in connection with a medical termination of pregnancy or foetal death in utero
- Patients who are unable to complete the questionnaire (due to a lack of proficiency in the language, cognitive impairments, etc.)
- Women deprived of their liberty and/or protected by law
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
他の:Period before
|
Cervical ripening will be offered to them in accordance with the approach chosen by the healthcare team following a discussion of her case at a team meeting. |
|
実験的:Period after
|
Choice of cervical ripening technique from the following: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta®, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon). |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Score of the first dimension of the QEVA questionnaire
時間枠:2 days after giving birth
|
Total score of the dimension: 'emotions during childbirth' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Evaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome. |
2 days after giving birth
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Score of the second dimension of the QEVA questionnaire
時間枠:2 days after giving birth
|
Total score of the dimension 'interactions with healthcare professionals' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 5 to 20, a higher score means a worse outcome. |
2 days after giving birth
|
|
Score of the third dimension of the QEVA questionnaire
時間枠:2 days after giving birth
|
Total score of the dimension 'first moments with the baby' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 3 to 12, a higher score means a worse outcome. |
2 days after giving birth
|
|
Score of the fourth dimension of the QEVA questionnaire
時間枠:2 days after giving birth
|
Total score of the dimension : 'feeling during the postpartum period' from the Questionnaire Assessing the Childbirth Experience (QACE / Questionnaire d'Évaluation du Vécu de l'Accouchement, QEVA in French). The score ranges from 4 to 16, a higher score means a worse outcome. |
2 days after giving birth
|
|
Procedures for informing patients about their experience of childbirth
時間枠:2 days after giving birth
|
Multiple choice: 1/information provided by a healthcare professional during a consultation (the patient's referring obstetrician or midwife), 2/our hospital's patient information leaflet, 3/antenatal classes, and 4/other sources (social media, etc.), expressed as percentages of the total number of participants. |
2 days after giving birth
|
|
Impact of the duration of antenatal care on the experience of childbirth
時間枠:At baseline
|
Assessment of the duration of care from the start of maturation to birth (days) |
At baseline
|
|
Impact of the maturation technique used on the experience of childbirth
時間枠:At baseline
|
Assessment of the impact of the ripening technique used on the childbirth experience for the following techniques: the 10 mg vaginal dinoprostone delivery system (Propess), oral misoprostol (Angusta, 25 µg tablets), 1 mg or 2 mg vaginal dinoprostone gel (Prostine) and the extra-amniotic balloon (Cook balloon) |
At baseline
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Cristina-Elena DOROFTE, MD、CHR Metz Thionville Hopital Femme Mère Enfant
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 2026-02-CHRMT
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。